CN101534826A - 治疗与年龄相关的黄斑变性（amd）的方法 - Google Patents

治疗与年龄相关的黄斑变性（amd）的方法 Download PDF

Info

Publication number
CN101534826A
CN101534826A CNA2007800222734A CN200780022273A CN101534826A CN 101534826 A CN101534826 A CN 101534826A CN A2007800222734 A CNA2007800222734 A CN A2007800222734A CN 200780022273 A CN200780022273 A CN 200780022273A CN 101534826 A CN101534826 A CN 101534826A
Authority
CN
China
Prior art keywords
optional substituted
group
base
amd
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800222734A
Other languages
English (en)
Chinese (zh)
Inventor
阿什利·布什
科林·L·马斯特斯
佩内洛普·J·哈金斯
杰克·G·帕森斯
盖克·B·科克
维加雅·肯切
玛丽安娜·埃尔索斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alterity Therapeutics Ltd
Original Assignee
Prana Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prana Biotechnology Ltd filed Critical Prana Biotechnology Ltd
Publication of CN101534826A publication Critical patent/CN101534826A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2007800222734A 2006-04-14 2007-04-13 治疗与年龄相关的黄斑变性（amd）的方法 Pending CN101534826A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79227806P 2006-04-14 2006-04-14
US60/792,278 2006-04-14

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN2010102559981A Division CN101987849B (zh) 2006-04-14 2007-04-13 治疗与年龄相关的黄斑变性(amd)的方法
CN2011101585377A Division CN102225930A (zh) 2006-04-14 2007-04-13 治疗与年龄相关的黄斑变性(amd)的方法

Publications (1)

Publication Number Publication Date
CN101534826A true CN101534826A (zh) 2009-09-16

Family

ID=38608967

Family Applications (3)

Application Number Title Priority Date Filing Date
CNA2007800222734A Pending CN101534826A (zh) 2006-04-14 2007-04-13 治疗与年龄相关的黄斑变性（amd）的方法
CN2011101585377A Pending CN102225930A (zh) 2006-04-14 2007-04-13 治疗与年龄相关的黄斑变性(amd)的方法
CN2010102559981A Expired - Fee Related CN101987849B (zh) 2006-04-14 2007-04-13 治疗与年龄相关的黄斑变性(amd)的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN2011101585377A Pending CN102225930A (zh) 2006-04-14 2007-04-13 治疗与年龄相关的黄斑变性(amd)的方法
CN2010102559981A Expired - Fee Related CN101987849B (zh) 2006-04-14 2007-04-13 治疗与年龄相关的黄斑变性(amd)的方法

Country Status (14)

Country Link
US (3) US20100144693A1 (https=)
EP (2) EP2514423A3 (https=)
JP (1) JP5290147B2 (https=)
KR (2) KR20080109096A (https=)
CN (3) CN101534826A (https=)
AU (2) AU2007240120A1 (https=)
BR (2) BRPI0710737A2 (https=)
CA (1) CA2683756A1 (https=)
DK (1) DK2012789T3 (https=)
ES (1) ES2437997T3 (https=)
IL (1) IL207495A (https=)
NZ (2) NZ590271A (https=)
WO (1) WO2007118276A1 (https=)
ZA (2) ZA200809493B (https=)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101589026A (zh) * 2006-06-22 2009-11-25 普拉纳生物技术有限公司 治疗脑神经胶质瘤的方法
CN105073714A (zh) * 2012-12-20 2015-11-18 奥尔德拉医疗公司 迫位原醇
CN107001360A (zh) * 2014-12-02 2017-08-01 普拉纳生物技术有限公司 4H‑吡啶并[1,2‑a]嘧啶‑4‑酮化合物
CN109232396A (zh) * 2018-11-27 2019-01-18 聊城大学 酰胺吡啶类衍生物及其用途
CN109414437A (zh) * 2016-07-01 2019-03-01 普拉纳生物技术有限公司 治疗免疫球蛋白轻链淀粉样变性的方法
US10550085B2 (en) 2015-08-21 2020-02-04 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
US11007157B2 (en) 2013-01-23 2021-05-18 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
CN113214249A (zh) * 2021-04-23 2021-08-06 成都大学 吡啶并[1,2-a]嘧啶-4-硫酮化合物的合成方法
US11129823B2 (en) 2016-05-09 2021-09-28 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
US11312692B1 (en) 2018-08-06 2022-04-26 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US11724987B2 (en) 2005-05-26 2023-08-15 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
US12029735B2 (en) 2019-05-02 2024-07-09 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12064516B2 (en) 2020-05-13 2024-08-20 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
US12097188B2 (en) 2009-12-11 2024-09-24 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
AU2009282480B2 (en) * 2008-08-11 2015-05-07 Children's Medical Center Corporation Halofuginone analogs for inhibition of tRNA synthetases and uses thereof
WO2010071944A1 (en) * 2008-12-24 2010-07-01 Prana Biotechnology Limited Quinazolinone compounds
CA2750599A1 (en) 2009-01-26 2010-07-29 Michael Spino Use of deferiprone for treatment and prevention of iron-related eye disorders
WO2012122534A2 (en) 2011-03-10 2012-09-13 The Trustees Of Columbia University In The City Of New York N-quinolin-benzensulfonamides and related compounds for the treatment of cancer, autoimmune disorders and inflammation
US10155742B2 (en) 2012-01-13 2018-12-18 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
US10111862B2 (en) 2013-01-25 2018-10-30 Aldeyra Therapeutics, Inc. Traps in the treatment of macular degeneration
EP3290969B1 (en) * 2015-04-29 2021-06-23 Triapex Co., Ltd. Polarizing lens including a polarizing film
US10781178B2 (en) * 2015-08-12 2020-09-22 The General Hospital Corporation 8-hydroxyquinoline derivatives as diagnostic and therapeutic agents
US11008290B2 (en) * 2015-09-24 2021-05-18 University Of Florida Research Foundation, Incorporated Halogenated quinoline derivatives as antimicrobial agents
CA3054811A1 (en) 2017-03-16 2018-09-20 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2019075136A1 (en) 2017-10-10 2019-04-18 Aldeyra Therapeutics, Inc. TREATMENT OF INFLAMMATORY DISORDERS
EP3801525A4 (en) 2018-06-08 2022-03-23 The General Hospital Corporation PROLYL TRNA SYNTHETASE INHIBITORS
US20230301984A1 (en) * 2020-07-02 2023-09-28 The Usa, As Represented By The Secretary, Department Of Health And Human Services Cyclic compounds for use in treating retinal degeneration
US12060334B2 (en) 2021-03-12 2024-08-13 University Of Florida Research Foundation, Incorporated 3-substituted phenazine derivatives as antimicrobial agents

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE505711A (https=) 1950-09-09
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
HU178910B (en) * 1977-08-19 1982-07-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing 2,3-disubstituted-4-oxo-4h-pyrido/1,2-a/-pyrimidines
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
IT1204612B (it) 1987-05-14 1989-03-10 Bioresearch Spa Pteridine atte alla preparazione di composizioni farmaceutiche ad attivita' antiamnesica
US5314909A (en) * 1993-03-17 1994-05-24 Merck & Co., Inc. Use of non-steroidal antiiflammatory agents in macular degeneration
JP3094373B2 (ja) 1993-04-08 2000-10-03 イデアール‐シユタンダルト ゲゼルシヤフト ミツト ベシユレンクテル ハフツング 衛生水栓
US5631373A (en) 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
DE4418096A1 (de) * 1994-05-24 1995-11-30 Cassella Ag Verwendung von Pteridin-Derivaten als Hemmstoffe der NO-Synthase
US6168776B1 (en) 1994-07-19 2001-01-02 University Of Pittsburgh Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US5801183A (en) 1995-01-27 1998-09-01 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists
CZ295118B6 (cs) * 1996-08-13 2005-05-18 P. N. Gerolymatos S. A. Farmaceutický prostředek
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
US5939421A (en) 1997-07-01 1999-08-17 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
US20020025944A1 (en) * 2000-04-28 2002-02-28 Bush Ashley I. Use of clioquinol for the therapy of Alzheimer's disease
US6337332B1 (en) * 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists
PL198852B1 (pl) 1998-10-22 2008-07-31 Neurosearch As Podstawione pochodne fenylu, kompozycja farmaceutyczna je zawierająca oraz ich zastosowanie
US6369058B1 (en) * 1999-02-04 2002-04-09 New Millennium Pharmaceutical Research Inc. Brain delivery of folic acid for the prevention of alzheimer's disease and stroke
WO2001016114A2 (en) 1999-08-27 2001-03-08 Chemocentryx, Inc. Heterocyclic compounds and methods for modulating cxcr3 function
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
FR2819187A1 (fr) * 2001-01-10 2002-07-12 Michel Xilinas Utilisation des substances chelatrices pour le traitement et la prevention de la deferrescence oculaire
ATE427948T1 (de) 2001-04-24 2009-04-15 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
FR2827599A1 (fr) * 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
CA2456155A1 (en) 2001-08-17 2003-02-27 Merck & Co., Inc. Process for preparing 5-sulfonamido-8-hydroxy-1, 6-naphthyridine-7-carboxamides
EP1477482B1 (en) 2002-02-20 2010-04-14 Ajinomoto Co., Inc. Novel phenylalanine derivative
ATE507210T1 (de) 2002-03-07 2011-05-15 X Ceptor Therapeutics Inc Chinazolinon modulatoren von nukleinrezeptoren
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
AU2002951868A0 (en) * 2002-10-04 2002-10-24 Prana Biotechnology Limited Compound i
JP4690043B2 (ja) * 2002-10-04 2011-06-01 プラナ バイオテクノロジー リミティッド 神経に対し活性な化合物
EP1617844A4 (en) * 2003-04-03 2009-07-22 Prana Biotechnology Ltd TREATMENT OF NEUROLOGICAL DISEASES
EP1644325A2 (en) * 2003-06-23 2006-04-12 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
NZ551004A (en) * 2004-04-02 2010-07-30 Prana Biotechnology Ltd Neurologically-active compounds
CA2593846A1 (en) * 2005-01-14 2006-08-10 The Regents Of The University Of California Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
WO2006117660A2 (en) * 2005-05-04 2006-11-09 Clio Pharmaceutical Corporation Method for treating cancer, coronary, inflammatory and macular disease, combining the modulation of zinc- and/or copper dependent proteins
US8163760B2 (en) * 2006-06-22 2012-04-24 Prana Biotechnology Limited Use of pyridopyrimidine compounds in the treatment of gliomas

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11724987B2 (en) 2005-05-26 2023-08-15 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
CN101589026A (zh) * 2006-06-22 2009-11-25 普拉纳生物技术有限公司 治疗脑神经胶质瘤的方法
US12097188B2 (en) 2009-12-11 2024-09-24 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
CN105073714A (zh) * 2012-12-20 2015-11-18 奥尔德拉医疗公司 迫位原醇
US11701331B2 (en) 2013-01-23 2023-07-18 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US12128013B2 (en) 2013-01-23 2024-10-29 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US11007157B2 (en) 2013-01-23 2021-05-18 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US11771664B2 (en) 2013-01-23 2023-10-03 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
CN107001360A (zh) * 2014-12-02 2017-08-01 普拉纳生物技术有限公司 4H‑吡啶并[1,2‑a]嘧啶‑4‑酮化合物
CN107001360B (zh) * 2014-12-02 2020-09-18 普拉纳生物技术有限公司 4H-吡啶并[1,2-a]嘧啶-4-酮化合物
CN111961050A (zh) * 2014-12-02 2020-11-20 普拉纳生物技术有限公司 4H-吡啶并[1,2-a]嘧啶-4-酮化合物
US11845722B2 (en) 2015-08-21 2023-12-19 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
US11459300B2 (en) 2015-08-21 2022-10-04 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
US12240816B2 (en) 2015-08-21 2025-03-04 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
US11046650B2 (en) 2015-08-21 2021-06-29 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
US10550085B2 (en) 2015-08-21 2020-02-04 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
US11129823B2 (en) 2016-05-09 2021-09-28 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
CN109414437A (zh) * 2016-07-01 2019-03-01 普拉纳生物技术有限公司 治疗免疫球蛋白轻链淀粉样变性的方法
US12006298B2 (en) 2018-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US11312692B1 (en) 2018-08-06 2022-04-26 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CN109232396A (zh) * 2018-11-27 2019-01-18 聊城大学 酰胺吡啶类衍生物及其用途
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
US12029735B2 (en) 2019-05-02 2024-07-09 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12064516B2 (en) 2020-05-13 2024-08-20 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
CN113214249B (zh) * 2021-04-23 2023-09-19 成都大学 吡啶并[1,2-a]嘧啶-4-硫酮化合物的合成方法
CN113214249A (zh) * 2021-04-23 2021-08-06 成都大学 吡啶并[1,2-a]嘧啶-4-硫酮化合物的合成方法

Also Published As

Publication number Publication date
NZ572591A (en) 2012-01-12
AU2010206074A1 (en) 2010-08-19
KR20080109096A (ko) 2008-12-16
CN101987849A (zh) 2011-03-23
CN102225930A (zh) 2011-10-26
JP5290147B2 (ja) 2013-09-18
KR20100110396A (ko) 2010-10-12
ES2437997T3 (es) 2014-01-15
WO2007118276A1 (en) 2007-10-25
CA2683756A1 (en) 2007-10-25
ZA201005922B (en) 2013-09-25
IL207495A (en) 2015-05-31
BRPI0710737A2 (pt) 2011-05-10
EP2012789A1 (en) 2009-01-14
BRPI0722382A2 (pt) 2012-06-05
NZ590271A (en) 2011-12-22
JP2009533356A (ja) 2009-09-17
CN101987849B (zh) 2013-05-08
US9163018B2 (en) 2015-10-20
US20140088122A1 (en) 2014-03-27
EP2012789B1 (en) 2013-09-25
IL207495A0 (en) 2010-12-30
EP2012789A4 (en) 2011-02-16
US20110071167A1 (en) 2011-03-24
EP2514423A2 (en) 2012-10-24
EP2514423A3 (en) 2012-12-19
AU2007240120A1 (en) 2007-10-25
US20100144693A1 (en) 2010-06-10
ZA200809493B (en) 2010-08-25
AU2007240120A2 (en) 2008-12-18
DK2012789T3 (da) 2013-12-16
AU2010206074B2 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
CN101987849B (zh) 治疗与年龄相关的黄斑变性(amd)的方法
CN101589026B (zh) 治疗脑神经胶质瘤的方法
TWI452039B (zh) 抗神經變性疾病用劑
TWI396532B (zh) 用視黃基衍生物治療眼疾之方法及組合物
US20040044022A1 (en) Agent for treating neurodegenerative disorders
KR20150013240A (ko) 당뇨병성 망막병증 및 기타 안과 질환의 치료 방법
CN102292078A (zh) 哺乳动物雷帕霉素靶蛋白的抑制
JP2001503370A (ja) 眼の神経損傷の処置に（２−イミダゾリン−２−イルアミノ）キノキサリンを使用する方法
Debefve et al. Video monitoring of neovessel occlusion induced by photodynamic therapy with verteporfin (Visudyne®), in the CAM model
KR102467953B1 (ko) 리소좀 축적 질환과 관련된 약제 조성물 및 용도
KR20170066432A (ko) 정신병적 장애를 치료하기 위한 방법 및 조성물
US10058611B2 (en) Use of α-(8-quinolinyloxy) mono-substituted phthalocyanine zinc for treatment of psoriasis
CA2187361A1 (en) Pharmaceutical composition for treating glaucoma containing terazosin
MXPA00013031A (es) Ureas y carbamatos de acidos carboxilicos n-heterociclicos e isoesteres, para las enfermedades de la vision y la memoria.
KR20240073798A (ko) 란소프라졸, 란소프라졸 n-옥사이드, 란소프라졸 n-옥사이드 대사체, 또는 란소프라졸 n-옥사이드 전구물질을 포함하는 신경계 질환 예방 또는 치료용 조성물
CA2711638C (en) 3-substituted-8-hydroxypyridino[1,2-a]pyrimidin-4-one compounds and their use in treating retinal degenerative diseases
US10092612B2 (en) Garcinia mangostana composition, medication and health food including the same
RU2440159C1 (ru) Способ торможения процессов пролиферации в сетчатке при ее повреждении
US20030212052A1 (en) Use of ursdeoxycholic acid for potentiation of the phototoxic effect of photodynamic therapy
Komatsu et al. A pharmacokinetic model of oral methylphenidate in the rat and effects
Fris The effect of single and repeated ultraviolet radiation on the anterior segment of the rabbit eye
WO2001082860A2 (en) Use of ursodeoxycholic acid for potentiation of the phototoxic effect of photodynamic therapy
HK1215566B (en) Anti-angiogenesis compound, intermediate and use thereof
HK1215566A1 (en) Anti-angiogenesis compound, intermediate and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090916